792913-83-8

Basic information

• Product Name: Carbamic acid, (4-hydroxy-1-methylcyclohexyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (4-hydroxy-1-methylcyclohexyl)-, 1,1-dimethylethyl ester (9CI);CarbaMic acid, (4-hydroxy-1-Methylcyclohexyl)-, 1,1-diMethylethyl ester;2-Methyl-2-propanyl(4-hydroxy-1-Methylcyclohexyl)carbaMate;tert-Butyl (4-hydroxy-1-Methylcyclohexyl)carbaMate;(4-Hydroxy-1-methyl-cyclohexyl)-carbamic acid tert-butyl ester;tert-butyl N-(4-hydroxy-1-methylcyclohexyl)carbamate;(4-hydroxy-1-methylcyclohexyl)Carbamic acid 1,1-dimethylethyl ester
• CAS NO: 792913-83-8
• Molecular Formula: C₁₂H₂₃NO₃
• Molecular Weight: 229.31592
• Product Categories: METHYL
• Mol File: 792913-83-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Carbamic acid, (4-hydroxy-1-methylcyclohexyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (4-hydroxy-1-methylcyclohexyl)-, 1,1-dimethylethyl ester (9CI)(792913-83-8)
• EPA Substance Registry System: Carbamic acid, (4-hydroxy-1-methylcyclohexyl)-, 1,1-dimethylethyl ester (9CI)(792913-83-8)

Safety Data

• Hazardous Substances Data: 792913-83-8(Hazardous Substances Data)

Usage

Uses

Used in Chemical Reactions:
Carbamic acid, (4-hydroxy-1-methylcyclohexyl)-, 1,1-dimethylethyl ester (9CI) is used as a reactant in various chemical reactions for its unique structural properties and reactivity.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Carbamic acid, (4-hydroxy-1-methylcyclohexyl)-, 1,1-dimethylethyl ester (9CI) is used as an intermediate in the synthesis of certain drugs, leveraging its chemical reactivity and structural characteristics to facilitate the production of medicinal compounds.
Used in Research and Development:
Carbamic acid, (4-hydroxy-1-methylcyclohexyl)-, 1,1-dimethylethyl ester (9CI) is employed as a research compound in academic and industrial laboratories, where its properties are studied to understand its potential applications and to develop new methodologies in organic chemistry.

Upstream product

• 1342811-04-4 C₂₁H₄₃NO₃Si 
• 1342811-03-3 C₁₇H₃₄O₃Si 
• 1342811-02-2 C₁₆H₃₂O₃Si 
• 1352615-11-2 ethyl 4-triisopropylsilyloxycyclohexylcarboxylate 
• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 
• 412293-43-7 tert-butyl N-(1-methyl-4-oxo-cyclohexyl)carbamate 

Downstream Products

• 412293-43-7 tert-butyl N-(1-methyl-4-oxo-cyclohexyl)carbamate 
• 1342811-05-5 C₁₇H₂₅BrN₄O₂ 
• 1447955-52-3 4-amino-4-methylcyclohexan-1-ol hydrochloride 
• 792913-84-9 tert-butyl 4-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)oxy]-1-methylcyclohexylcarbamate 

Relevant articles and documents

INHIBITORS OF RAF KINASES

Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS DPP-IV INHIBITORS

A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X is CFH, or CF?2#191, R?1? is the moiety represented by the formula: [wherein R?2? is (lower) alkyl, R?3? is phenyl-(lower)alkyl, and the like.], and the like.] Compounds of formula (I) inhibit DPP-IV activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as NIDDM.